Substantial research demonstrates that preventive care – including vaccination programs, services encouraging physical activity, and technologies such as genetic testing – is often more efficient and cost effective than treatment of preventable diseases and their associated risk factors.
As these advances in research and product development move forward, misalignment on what are considered optimal levels of preventive care among payers can create challenges for healthcare systems. In this PM360 article, Michele Pistollato, Rajini Jayasuriya, and Elaine Damato analyse the barriers to reimbursement for preventive care, how payer views might shift over the next decade, and how drug and technology companies focusing on preventive programs can optimize their strategies as the sector evolves.
The authors wish to acknowledge the contributions of Lev Gerlovin and Neil Turner to this article.
